These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 30027591

  • 21. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [Abstract] [Full Text] [Related]

  • 22. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [Abstract] [Full Text] [Related]

  • 23. The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax.
    Yilmaz U, Komek H, Can C, Altindag S.
    Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
    [Abstract] [Full Text] [Related]

  • 24. The use of 68  Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.
    Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, Gianduzzo T.
    BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
    [Abstract] [Full Text] [Related]

  • 25. The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients.
    Su HC, Zhu Y, Hu SL, Liu C, Lin GW, Dai B, Zhang YJ, Ye DW.
    Ann Surg Oncol; 2019 Feb; 26(2):653-659. PubMed ID: 30324468
    [Abstract] [Full Text] [Related]

  • 26. Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics.
    García-Zoghby L, Amo-Salas M, Soriano Castrejón ÁM, García Vicente AM.
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2467-2483. PubMed ID: 38520513
    [Abstract] [Full Text] [Related]

  • 27. An Australian experience using Tc-PSMA SPECT/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy.
    Duncan I, Ingold N, Martinez-Marroquin E, Paterson C.
    Prostate; 2023 Jul; 83(10):970-979. PubMed ID: 37051636
    [Abstract] [Full Text] [Related]

  • 28. Role of PET-CT with 18F-fluorocholine in biochemical recurrence after treatment of prostate cancer with curative intent.
    Puche-Sanz I, Triviño-Ibáñez E, Vázquez-Alonso F, Llamas-Elvira JM, Cózar-Olmo JM, Rodríguez-Fernández A.
    Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
    [Abstract] [Full Text] [Related]

  • 29. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis.
    Treglia G, Ceriani L, Sadeghi R, Giovacchini G, Giovanella L.
    Clin Chem Lab Med; 2014 May; 52(5):725-33. PubMed ID: 24310773
    [Abstract] [Full Text] [Related]

  • 30. 99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.
    Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, van Leeuwen FWB, Haller B, Horn T, Heck MM, Gschwend JE, Schwaiger M, Wester HJ, Eiber M.
    Eur Urol; 2019 Apr; 75(4):659-666. PubMed ID: 29625755
    [Abstract] [Full Text] [Related]

  • 31. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.
    De Bari B, Mazzola R, Aiello D, Fersino S, Gregucci F, Alongi P, Nicodemo M, Cavalleri S, Salgarello M, Alongi F.
    Radiol Med; 2018 Sep; 123(9):719-725. PubMed ID: 29687208
    [Abstract] [Full Text] [Related]

  • 32. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.
    Mamede M, Ceci F, Castellucci P, Schiavina R, Fuccio C, Nanni C, Brunocilla E, Fantini L, Costa S, Ferretti A, Colletti PM, Rubello D, Fanti S.
    Clin Nucl Med; 2013 Sep; 38(9):e342-5. PubMed ID: 23797218
    [Abstract] [Full Text] [Related]

  • 33. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.
    Francolini G, Detti B, Bottero M, Zilli T, Lancia A, Bruni A, Borghesi S, Mariotti M, Castellucci P, Fanti S, Filippi AR, Teriaca MA, Maragna V, Aristei C, Mazzeo E, Livi L, Ingrosso G.
    Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U.
    Radiat Oncol; 2017 Nov 10; 12(1):176. PubMed ID: 29126446
    [Abstract] [Full Text] [Related]

  • 36. Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial.
    Zhang Y, Lin Z, Li T, Wei Y, Yu M, Ye L, Cai Y, Yang S, Zhang Y, Shi Y, Chen W.
    Sci Rep; 2022 Sep 26; 12(1):15993. PubMed ID: 36163353
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.
    Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner FP, Kübler H, Haberkorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M.
    J Nucl Med; 2015 May 26; 56(5):668-74. PubMed ID: 25791990
    [Abstract] [Full Text] [Related]

  • 38. Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study.
    Gacci M, Cai T, Siena G, Minervini A, Torshizi MF, Bartolini M, Giannì G, Saieva C, Ceroti M, Detti B, Livi L, Pupi A, Carini M.
    Scand J Urol; 2014 Jun 26; 48(3):259-67. PubMed ID: 24255954
    [Abstract] [Full Text] [Related]

  • 39. Usefulness of 18F-fluorocoline PET/CT in prostate cancer patients with biochemical recurrence: Influence of PSA kinetics and hormone therapy.
    Triviño-Ibáñez EM, Puche-Sanz I, Gómez-Río M, Cózar Olmo JM, Llamas-Elvira JM, Rodríguez-Fernández A.
    Med Clin (Barc); 2019 Jul 19; 153(2):56-62. PubMed ID: 30660434
    [Abstract] [Full Text] [Related]

  • 40. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA, Halvorsen OJ, Daehlin L, Hostmark J, Akslen LA.
    BJU Int; 2006 Jan 19; 97(1):51-5. PubMed ID: 16336328
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.